PHOENIX--(BUSINESS WIRE)--Synovics Pharmaceuticals, Inc. (OTCBB:SYVC), a specialty pharmaceutical company, today announced that its wholly owned subsidiary ANDAPharm LLC, has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for approval of its formulation of a 10mg dose of hydroxyzine HCL. Hydroxyzine HCL is sold under the brand names of Atarax®. The U.S. market for 10mg hydroxyzine HCL is $40 million.
